about
Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsionsNanomedicine strategies for molecular targets with MRI and optical imaging.Improved molecular imaging contrast agent for detection of human thrombus.Targeted PARACEST nanoparticle contrast agent for the detection of fibrin.Spectral properties of a bifunctional PARACEST europium chelate: an intermediate for targeted imaging applications.Quantification of water exchange kinetics for targeted PARACEST perfluorocarbon nanoparticles.Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles.Magnetic resonance chemical exchange saturation transfer imaging and nanotechnology.Quantitative cardiovascular magnetic resonance for molecular imaging.Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery.Magnetic resonance molecular imaging with nanoparticles.MR molecular imaging of aortic angiogenesis.Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy.1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles.Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology.Molecular imaging by MRI.Nanomedicine opportunities in cardiology.Molecular imaging and therapy of atherosclerosis with targeted nanoparticles.Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbitsGadolinium-modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging.Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imagingMolecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticlesAntiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosisAngiogenesis imaging with vascular-constrained particles: the why and how.Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles.Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles.Assessment of tumor angiogenesis: dynamic contrast-enhanced MRI with paramagnetic nanoparticles compared with Gd-DTPA in a rabbit Vx-2 tumor model.In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla.Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI.An MRI system for imaging neonates in the NICU: initial feasibility study.A novel europium(III)-based MRI contrast agent.Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles.Molecular imaging of human thrombus with computed tomography.Triple-quantum-filtered (23)Na NMR spectroscopy of subcutaneously implanted 9l gliosarcoma in the rat in the presence of TmDOTP(5-1).Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technologyTargeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosisEndothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosisImproving the homogeneity of DNA patterning on microarrays
P50
Q30474759-7AC92677-43AE-4582-876F-A8286A641C58Q30481471-74E6555A-BFDC-4CA9-BB82-4463C1B9302DQ30813630-FEDD10B9-EBB8-464E-AFDA-66E27B621418Q31074409-297EDB06-5E8F-43AA-BDAC-608BAA54C02DQ31103029-A4144F62-0999-4CCC-A9C1-1A68A9091A28Q33959557-52CD1AB8-7D07-4C3D-BBF9-D356B2B8951AQ34033191-178286E0-C7FA-4F8A-8AEE-2DB5507F58A2Q34197669-7FCEC50F-C60F-43F8-AFB4-4C68D2C272A6Q34330885-A22D1777-C798-414B-BD02-97121F12C1F2Q35972343-21F9601B-037F-4DDF-8FC6-55D92990BEE6Q35980840-2E91715B-2DED-4CE3-B95B-E576FA6A8814Q36182417-340BCB8B-2B42-4B22-A4F8-273583132CF0Q36216849-C8B061B3-F7ED-4C30-A0D6-8DE901A6F547Q36336344-B187282F-B132-40C5-A5FD-8CBEEB8993DFQ36350939-6D85E8C6-F325-4898-A115-EC911A4F614FQ36409278-6FC20E93-AEA7-4B10-BBA8-82790F58A148Q36667383-14F2E3AE-7A58-455B-9237-1DA2819FE243Q36755497-5FA2F529-53B5-4C01-8C23-75B06352C8ADQ36759502-0759F7DC-9F27-4624-93AD-1EF7793D7934Q36804990-D1D39743-6D9F-48A4-880E-CA4A2213BF7EQ37003678-BB0B9436-261B-4F92-97F0-E37FB915B129Q37003713-A3850ED2-0D35-4938-87BB-ED277A64E5A3Q37039546-B19B6968-F763-4064-A3EF-087C4097B506Q37085672-4377135E-473A-41FF-A07E-446BE37A1074Q37771304-41839DA5-4270-45C9-9809-AD7AC097C1ACQ40465620-D7B90727-2403-4E2D-B119-F614343F902EQ44616397-C399181B-0D09-4890-8E82-84A451B48F2AQ45905154-92289C9F-377E-4355-824A-A45A4DDEBE88Q46947352-B4175E28-4414-462C-AEA9-50C58ECBE004Q47990066-52272C29-2A32-438B-88B6-2CEB241656F4Q48459740-79BF68FE-857E-4D90-90ED-EF86B513DAF5Q49305132-4CA7809E-5E3F-43A5-AC7A-FF6968908291Q51538099-CBF0F351-52C7-41CF-9BA3-C1D7BE7288F8Q53573524-7B008144-1EAF-4BFF-89CC-64AA72D3EE51Q55474081-D2D7E4CF-B71B-4351-9FA3-E28941FD851AQ74631087-CE3D2AE3-5509-4BCC-93F8-68DBDA94F5C6Q78570662-4FB4FA2E-3692-4B18-89BE-BDE5561B00FBQ79851922-728109A7-DF54-4BB4-A4C0-2BBFDFB79E49Q95788472-A65EC83A-3DD5-4CE9-91CA-9E11F071D1AA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Patrick Winter
@ast
Patrick Winter
@en
Patrick Winter
@es
Patrick Winter
@nl
Patrick Winter
@sl
Патрик Винтер
@ru
type
label
Patrick Winter
@ast
Patrick Winter
@en
Patrick Winter
@es
Patrick Winter
@nl
Patrick Winter
@sl
Патрик Винтер
@ru
prefLabel
Patrick Winter
@ast
Patrick Winter
@en
Patrick Winter
@es
Patrick Winter
@nl
Patrick Winter
@sl
Патрик Винтер
@ru
P106
P1153
7202002707
P21
P31
P496
0000-0001-5975-5465